Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)

AM-Pharma

Attachments

*Architects: Diabetes, Metabolic Disease, Dialysis, Renal & Kidney Companies (Pharmaceuticals, Biotechnology, Biosimilars)
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
*Industry: Netherlands
Venture Capital: Series D

AM-Pharma Raises €29.2m in Series D Financing (2011)
Bunnik, The Netherlands
Clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis
Founded 2002
Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.
Series D $39.8M by OnBioVC (2011)